MXPA04003878A - Combinaciones que comprenden un inhibidor selectivo de cicloxigenasa-2. - Google Patents

Combinaciones que comprenden un inhibidor selectivo de cicloxigenasa-2.

Info

Publication number
MXPA04003878A
MXPA04003878A MXPA04003878A MXPA04003878A MXPA04003878A MX PA04003878 A MXPA04003878 A MX PA04003878A MX PA04003878 A MXPA04003878 A MX PA04003878A MX PA04003878 A MXPA04003878 A MX PA04003878A MX PA04003878 A MXPA04003878 A MX PA04003878A
Authority
MX
Mexico
Prior art keywords
inhibitor
combinations
growth factor
factor receptor
receptor tyrosine
Prior art date
Application number
MXPA04003878A
Other languages
English (en)
Inventor
Pan Chen Ying-Nan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA04003878A publication Critical patent/MXPA04003878A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Se describe una terapia de combinacion para tratar pacientes que sufren de lesiones de colon pre-malignas (por ejemplo, polipos) y cancer de colon, asi como otras malignidades. El paciente es tratado concurrentemente con un inhibidor de ciclooxigenasa-2 y por lo menos un compuesto seleccionado del grupo que consiste de un agente de interferencia de microtubulo, un inhibidor de cinasa de proteina de tirosina de receptor de factor de crecimiento epitelial y un inhibidor de cinasa de tirosina de receptor de factor de crecimiento endotelial vascular.
MXPA04003878A 2001-10-25 2002-10-24 Combinaciones que comprenden un inhibidor selectivo de cicloxigenasa-2. MXPA04003878A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34473501P 2001-10-25 2001-10-25
US34473401P 2001-10-25 2001-10-25
US33603301P 2001-11-15 2001-11-15
PCT/EP2002/011924 WO2003035047A2 (en) 2001-10-25 2002-10-24 Combinations comprising a selective cyclooxygenase-2 inhibitor

Publications (1)

Publication Number Publication Date
MXPA04003878A true MXPA04003878A (es) 2004-07-08

Family

ID=27407094

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003878A MXPA04003878A (es) 2001-10-25 2002-10-24 Combinaciones que comprenden un inhibidor selectivo de cicloxigenasa-2.

Country Status (23)

Country Link
US (2) US20050043409A1 (es)
EP (1) EP1441714B1 (es)
JP (1) JP2005506366A (es)
KR (1) KR100954625B1 (es)
CN (1) CN100506224C (es)
AT (1) ATE381930T1 (es)
AU (2) AU2006252156A1 (es)
BR (1) BR0213486A (es)
CA (1) CA2464309C (es)
CY (1) CY1108045T1 (es)
DE (1) DE60224299T2 (es)
DK (1) DK1441714T3 (es)
ES (1) ES2295428T3 (es)
HK (1) HK1068261A1 (es)
HU (1) HUP0600235A3 (es)
IL (1) IL161462A0 (es)
MX (1) MXPA04003878A (es)
NZ (2) NZ552335A (es)
PL (1) PL369305A1 (es)
PT (1) PT1441714E (es)
RU (1) RU2333754C2 (es)
SI (1) SI1441714T1 (es)
WO (1) WO2003035047A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
DE602004017479D1 (de) 2003-08-29 2008-12-11 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
EP1667721A2 (en) * 2003-09-23 2006-06-14 Novartis AG Combinations of a vegf receptor inhibitor with other therapeutic agents
JP2007505938A (ja) * 2003-09-23 2007-03-15 ノバルティス アクチエンゲゼルシャフト Ｖｅｇｆ受容体阻害剤と化学療法剤の組み合わせ
BRPI0418102A (pt) 2003-12-23 2007-04-27 Pfizer derivados de quinolina
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
RU2419430C2 (ru) * 2006-02-09 2011-05-27 Дайити Санкио Компани, Лимитед Противораковая фармацевтическая композиция
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
CA2855243C (en) 2011-11-11 2020-04-14 Novartis Ag Method of treating a proliferative disease
MD565Z (ro) * 2012-05-23 2013-07-31 Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы Procedeu de tratare a seminţelor de sfeclă de zahăr

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0932402B1 (en) * 1996-10-15 2004-07-21 G.D. Searle LLC Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US6887893B1 (en) * 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
EP1140182A2 (en) * 1998-12-23 2001-10-10 G.D. Searle & Co. Use of a matrix metalloproteinase inhibitor together with an antineoplastic agent, optionally also together with radiation, in the treatment of neoplasia
IL147913A0 (en) * 1999-08-12 2002-08-14 American Cyanamid Co Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
YU35102A (sh) * 1999-12-03 2005-03-15 Pfizer Products Inc. Derivati heterociklo-alkilsulfonil pirazola kao anti- inflamatorni/analgetički agensi
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
EP1259237A4 (en) * 2000-02-17 2004-07-28 Merck & Co Inc TREATMENT OR PREVENTION OF PROSTATE CANCER USING A SELECTIVE COX-2 INHIBITOR MEDICINE
JP2003523390A (ja) * 2000-02-25 2003-08-05 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害薬
CA2401697A1 (en) * 2000-03-03 2001-09-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer

Also Published As

Publication number Publication date
AU2010200433A1 (en) 2010-02-25
ATE381930T1 (de) 2008-01-15
NZ552335A (en) 2008-11-28
KR100954625B1 (ko) 2010-04-27
US20050043409A1 (en) 2005-02-24
EP1441714A2 (en) 2004-08-04
CN1575168A (zh) 2005-02-02
WO2003035047A2 (en) 2003-05-01
HUP0600235A3 (en) 2008-04-28
DE60224299D1 (de) 2008-02-07
CA2464309C (en) 2012-01-03
DE60224299T2 (de) 2008-12-11
PL369305A1 (en) 2005-04-18
KR20040048992A (ko) 2004-06-10
CY1108045T1 (el) 2013-09-04
JP2005506366A (ja) 2005-03-03
PT1441714E (pt) 2008-03-10
RU2333754C2 (ru) 2008-09-20
WO2003035047A3 (en) 2003-10-23
HUP0600235A2 (en) 2007-02-28
RU2004116069A (ru) 2005-06-10
CN100506224C (zh) 2009-07-01
IL161462A0 (en) 2004-09-27
NZ532418A (en) 2007-02-23
HK1068261A1 (en) 2005-04-29
BR0213486A (pt) 2005-05-10
SI1441714T1 (sl) 2008-06-30
US20110046190A1 (en) 2011-02-24
ES2295428T3 (es) 2008-04-16
AU2006252156A1 (en) 2007-01-18
CA2464309A1 (en) 2003-05-01
EP1441714B1 (en) 2007-12-26
DK1441714T3 (da) 2008-03-31

Similar Documents

Publication Publication Date Title
HK1068261A1 (en) Combinations comprisinga selective cyclooxygenase-2 inhibitor
IL154949A0 (en) Imidazole derivatives as raf kinase inhibitors
MY151032A (en) Treatment of tnf? related disorders
WO2004050026A3 (en) Compositions and methods for treating prostate cancer
WO2001032155A3 (en) Use of egfr tyrosine kinase inhibitors for treating breast cancer
MY135477A (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
WO2003049702A3 (en) Vanilloid receptor ligands and their use in treatments
AU2002340168A1 (en) Treatment of prostate cancer by inhibitors of ncam2
TNSN04015A1 (en) Combination therapy for the treatment of cancer
WO2001062784A3 (en) Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
WO2002074756A3 (de) Urokinase-inhibitoren
IL160382A0 (en) Use of 4-pyridylmethylphthalazines for cancer treatment
RS37804A (en) Use of n,n-diethyl-2-/-4-(phenylmethyl)- phenoxy/ethanamine monohydrochloride (dppe)in cancer therapy
BRPI0411126A (pt) derivados de 1,3,4-triaza-fenaleno e 1,3,4,6-tetraazafenaleno
WO2001079505A3 (en) INHIBITION OF BONE TUMOR FORMATION USING ANTISENSE cDNA THERAPY
AU2002348101A1 (en) Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
UA49216A (uk) Засіб для лікування ускладнень після видалення злоякісних новоутворень шкіри
WO2004044226A3 (en) Induction of cellular senescence by cdk4 disruption for tumor supression and regression
MXPA04002407A (es) Uso de 4-piridilmeetil-ftalazinas para el tratamiento de cancer.
UA67528A (en) Method for surgical treatment of thyroid cancer
AU2002359762A1 (en) Luminacin analogs and uses thereof
UA41034A (uk) Спосіб лікування хворих із злоякісними пухлинами сечового міхура
AU2013204153A1 (en) Treatment of TNFalpha related disorders
AU2001265906A1 (en) Chemical alteration of mammal urine and mammal blood

Legal Events

Date Code Title Description
FG Grant or registration